CYBX

Overview

Highlights

News

Chart

Contacts

 

   
 
   
"Announced 4th Quarter net earnings for 2008 of $2.9 million, compared with a net loss of $10.8 million for 2007.  
   
   
Approximate Financial Snapshot as of 6/12/08
Shares Outstanding 27.4M
52 Wk Hi/Lo 18.50/

9.59

Market Cap $471M
Recent Price $17.19

 

 

Join the SmallCapReview mailing list
Email:

 

6/12/08

Cyberonics (CYBX)

Website: www.cyberonics.com

Pioneer of the Vagus Nerve Stimulation


Overview

Cyberonics (Nasdaq: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in 1987 to design, develop and market implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders, Cyberonics has emerged as a leader in the neuromodulation industry.

The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve in the left side of the neck. This therapy has proven effective in significantly reducing the number and/or intensity of seizures in many people suffering from epilepsy and has the potential for use in the treatment of other inadequately treated, chronic disorders.

In 1997, Cyberonics received approval from the Food and Drug Administration (FDA) to market VNS Therapy for the treatment of epilepsy. Since that time, more than 32,000 patients worldwide have been implanted with the device. These patients have accumulated in excess of 100,000 patient years of experience using this life-enhancing therapy.

The remarkable success of VNS Therapy in the treatment of epilepsy has served as a platform for continued innovation. In July, 2005 , after seven years of extensive study and clinical trials, VNS Therapy was approved by the FDA as a long-term adjunctive treatment for treatment-resistant depression. It is also at various levels of study as a potential treatment for other chronic disorders, including anxiety, Alzheimer’s, bulimia, and migraine headaches.


CYBX Investor Highlights

  • CYBX announced 4th Quarter net sales of $33.9 million, an 8% increase from $31.4 million.
  • Announced 4th Quarter net earnings of $2.9 million, including $1.3 million in insurance recoveries and $0.4 million in state tax credits, compared with a net loss of $10.8 million.
  • Earnings per diluted share of $0.11 cents, compared with a loss of $0.42 cents per share.
  • International net sales increased by 32% in fiscal 2008 to a record $26.3 million, up from the $19.9 million reported in fiscal 2007.

Recent News and Press Releases

Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2009 First Quarter

Cyberonics Board of Directors Nominates Joseph E. Laptewicz

Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference

Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter

Cyberonics Announces 2008 Bank Of America Health Care Conference Presentation

For the latest Quote and News on CYBX Click Here.


Three Month Chart




Contacts

Cyberonics Inc.

Cyberonics Building
100 Cyberonics Boulevard
Houston, TX 77058-2072
Phone: 281-228-7200


SEC Filings

CYBX filings with the SEC can be found here. All Fillings are current and the Company is fully reporting.


Disclaimer

SmallCapReview.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of CYBX, please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), SmallCapReview.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview.com web site. SmallCapReview.com has not been compensated for its efforts in presenting the Cyberonics profile on its website and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.